Abstract
Figure S10. Enhanced stromal-tumor proximity in drug-resistant niches. (A-B) Quantitative analysis of CAF-tumor cell distances in (A) treatment-naïve versus (B) Osimertinib-resistant tissues (corresponding to Figure 1J), demonstrating significantly closer association in resistant tumors. (C-D) Spatial analysis of CAF distribution in (C) untreated versus (D) relapsed tumors (from Figure 2Q), revealing preferential peri-tumoral localization of RGS5+MYL9+ CAFs following therapy. Error bars indicate mean ± SD, with statistical significance marked as ns, not significant, *P <0.05, **P <0.01, ***P <0.001 based on one-way ANOVA followed by Dunnett’s tests.